TOI:NASDAQThe Oncology Institute, Inc. Analysis

Starling Oncology Inc trades at $5.13, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it gained 15.7%.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 63.7% above the current price. Revenue is growing at 41.2% on a -8.0% profit margin.
Risk scores 3 out of 10, which is low for this asset class. With a beta of 0.42 and a maximum drawdown of 6.9%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.